Depakote Tapering Guide
valproate / divalproex
Boxed Warning
Hepatotoxicity (especially in children under 2), severe teratogenicity (neural tube defects, decreased IQ), and pancreatitis.
Overview
Valproate (divalproex sodium) is an anticonvulsant used for bipolar disorder (especially mania), epilepsy, and migraine prevention. Carries a black-box warning for hepatotoxicity, pancreatitis, and severe teratogenicity.
125mg, 250mg, 500mg DR; 250mg, 500mg ER; sprinkle capsules 125mg
Tablets DR: 125mg, 250mg, 500mg; Tablets ER: 250mg, 500mg; Capsules (sprinkle): 125mg; Oral solution: 250mg/5mL
Category X (mood/migraine indications); Category D (epilepsy)
Mechanism of Action
Increases GABA, blocks voltage-gated sodium channels, modulates T-type calcium channels. Multiple mechanisms with no single dominant target.
Taper Notes
Slow taper over weeks. In bipolar disorder, plan continuity of mood coverage.
Hyperbolic Tapering Guidance
Valproate withdrawal in mood disorders carries relapse risk. Slow taper with mood monitoring; consider cross-titration to alternative stabilizer where appropriate.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
3-7 days after stopping
1-3 weeks
4-8 weeks for most non-seizure symptoms
Mood instability can persist months without an alternative stabilizer
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Lamotrigine — valproate doubles lamotrigine levels (Stevens-Johnson syndrome risk)
- Carbamazepine, phenytoin, rifampin — decrease valproate levels
- Aspirin — displaces valproate from protein binding
Contraindications
- Mitochondrial disorders (POLG mutations)
- Severe hepatic impairment
- Urea cycle disorders
Toxicity
Hepatotoxicity, pancreatitis, hyperammonemic encephalopathy, thrombocytopenia, pancytopenia, weight gain, hair loss, tremor, PCOS-like features in women, neural tube defects in pregnancy.
Pharmacokinetics
ADME Profile
Hepatic via beta-oxidation, glucuronidation, CYP2C9, CYP2C19.
~90%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Depakote (valproate / divalproex) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Goodwin GM, Haddad PM, Ferrier IN, et al. 2016 — Discontinuation of mood stabilizers: practical considerations and review (Journal of Psychopharmacology)
- Geddes JR, Burgess S, Hawton K, et al. 2004 — Discontinuation of lithium augmentation in elderly patients (American Journal of Psychiatry)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- International Society for Bipolar Disorders (ISBD) — Specialty society guidance for bipolar maintenance pharmacotherapy
- Deprescribing.org — Clinician-facing deprescribing algorithms
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — mood stabilizer tapering forum — Community archive of mood-stabilizer discontinuation experiences
- Mad in America — mood stabilizer coverage — Independent journalism on lithium, lamotrigine, and valproate
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of mood-stabilizer adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.